2-Thiophenecarboxamide, N-[(1R,6R)-6-amino-2,2-difluorocyclohexyl]-4-(6-chloropyrazolo[1,5-a]pyrimidin-3-yl)-5-methyl- manufacturers
- MARK-IN-2
-
- $2120.00
-
2026-07-27
- CAS:1314893-26-9
- Purity:
- Supply Ability: 10g
- MARK-IN-2
-
- $2120.00
-
2026-07-27
- CAS:1314893-26-9
- Purity:
- Supply Ability: 10g
- MARK-IN-2
-
- $2120.00
-
2025-07-17
- CAS:1314893-26-9
- Purity:
- Supply Ability: 10g
|
| | 2-Thiophenecarboxamide, N-[(1R,6R)-6-amino-2,2-difluorocyclohexyl]-4-(6-chloropyrazolo[1,5-a]pyrimidin-3-yl)-5-methyl- Basic information |
| | 2-Thiophenecarboxamide, N-[(1R,6R)-6-amino-2,2-difluorocyclohexyl]-4-(6-chloropyrazolo[1,5-a]pyrimidin-3-yl)-5-methyl- Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | color | Light yellow to yellow |
| | 2-Thiophenecarboxamide, N-[(1R,6R)-6-amino-2,2-difluorocyclohexyl]-4-(6-chloropyrazolo[1,5-a]pyrimidin-3-yl)-5-methyl- Usage And Synthesis |
| Description | MARK-IN-2 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC50 of 5 nM. MARK-IN-2 (Compound 27) is a potent MARK inhibitor. Inhibition of MARK represents a potentially attractive means of arresting neurofibrillary tangle pathology in Alzheimer's disease. MARK-IN-2 inhibits MARK3 with an IC50 of 5 nM. MARK-IN-2 also inhibits MARK3 in primary cell culture of rat cortical neurons with an IC50 of 280 nM[1]. Characterization of the i.v. pharmacokinetic properties of MARK-IN-2 in rat and dog reveals reasonable volumes of distribution but moderate to high clearance and short half-lives. MARK-IN-2 (Compound 27) has moderate terminal elimination half-life (t1/2=0.7 h, and 1 h for rat and dog) [1]. | | Uses | MARK-IN-2 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC50 of 5 nM. | | in vivo | Characterization of the i.v. pharmacokinetic properties of MARK-IN-2 in rat and dog reveals reasonable volumes of distribution but moderate to high clearance and short half-lives. MARK-IN-2 (Compound 27) has moderate terminal elimination half-life (t1/2=0.7 h, and 1 h for rat and dog) [1]. | | References | [1]. Sloman DL, et al. Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties. Bioorg Med Chem Lett. 2016 Sep 1;26(17):4362-6. |
| | 2-Thiophenecarboxamide, N-[(1R,6R)-6-amino-2,2-difluorocyclohexyl]-4-(6-chloropyrazolo[1,5-a]pyrimidin-3-yl)-5-methyl- Preparation Products And Raw materials |
|